Intracellular localization and intercellular heterogeneity of the human DNA repair protein O-6 methylguanine-DNA methyltransferase

被引:64
作者
Belanich, M
Randall, T
Pastor, MA
Kibitel, JT
Alas, LG
Dolan, ME
Schold, SC
Gander, M
Lejeune, FJ
Li, BFL
White, AB
Wasserman, P
Citron, ML
Yarosh, DB
机构
[1] UNIV CHICAGO, HEMATOL ONCOL SECT, CHICAGO, IL 60637 USA
[2] SW MED CTR, DEPT NEUROL, DALLAS, TX 75235 USA
[3] CHU VAUDOIS, CTR PLURIDISCIPLINAIRE ONCOL, CH-1011 LAUSANNE, SWITZERLAND
[4] NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SINGAPORE 117548, SINGAPORE
[5] LONG ISL JEWISH MED CTR, NEW HYDE PK, NY 11042 USA
关键词
alkyltransferase; 1,3-bis(2-chlorethyl)-1-nitrosourea; carmustine; O-6-benzylguanine; temozolomide;
D O I
10.1007/s002800050427
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
O-6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl adducts from DNA and may be important in tumor resistance to alkylation chemotherapy. MGMT was visualized in human cells and tumor tissues with monoclonal antibodies against MGMT and immunofluorescence microscopy, and fluorescent signals were quantified by digital image analysis. MGMT was found both in the cytoplasm and the nucleus, and in either locale the protein reacts with alkylated DNA bases and becomes inactivated and lost from the cell. Cell lines in culture and xenografts showed a broad normal distribution of nuclear MGMT levels, but human brain tumors often showed a skewed distribution, with a significant fraction of cells with high levels of MGMT. O-6-Benzylguanine, a suicide substrate inactivator for MGMT activity, reduced MGMT in human cells and in a mouse xenograft to levels undetectable by antibody assay 1 h post-treatment. In melanoma specimens taken from a patient 3 h post-treatment with temozolomide, MGMT levels were reduced by 70%. This quantitative immunofluorescence assay can be used to monitor MGMT and its depletion in human tumors to improve the use of alkylating agents in cancer chemotherapy.
引用
收藏
页码:547 / 555
页数:9
相关论文
共 20 条
  • [1] AABO K, 1994, CANCER RES, V54, P3295
  • [2] AYI TC, 1992, CANCER RES, V52, P6423
  • [3] BELANICH M, 1994, ONCOL RES, V6, P129
  • [4] BRENT T, 1993, ONCOL RES, V5, P1
  • [5] CITRON M, 1991, CANCER RES, V51, P4131
  • [6] DETECTION OF MESSENGER-RNA FROM O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE MGMT IN HUMAN NORMAL AND TUMOR-TISSUES
    CITRON, M
    GRAVER, M
    SCHOENHAUS, M
    CHEN, S
    DECKER, R
    KLEYNERMAN, L
    KAHN, LB
    WHITE, A
    FORNACE, AJ
    YAROSH, D
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (05) : 337 - 340
  • [7] DEPLETION OF MAMMALIAN OXYGEN-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY BY OXYGEN-6-BENZYLGUANINE PROVIDES A MEANS TO EVALUATE THE ROLE OF THIS PROTEIN IN PROTECTION AGAINST CARCINOGENIC AND THERAPEUTIC ALKYLATING-AGENTS
    DOLAN, ME
    MOSCHEL, RC
    PEGG, AE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (14) : 5368 - 5372
  • [8] TREATMENT OF SUBCUTANEOUS AND INTRACRANIAL BRAIN-TUMOR XENOGRAFTS WITH O-6-BENZYLGUANINE AND 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA
    FELKER, GM
    FRIEDMAN, HS
    DOLAN, ME
    MOSCHEL, RC
    SCHOLD, C
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (06) : 471 - 476
  • [9] ALKYLTRANSFERASE TRANSGENIC MICE - PROBES OF CHEMICAL CARCINOGENESIS
    GERSON, SL
    ZAIDI, NH
    DUMENCO, LL
    ALLAY, E
    FAN, CY
    LIU, L
    OCONNOR, PJ
    [J]. MUTATION RESEARCH, 1994, 307 (02): : 541 - 555
  • [10] ISHIBASHI T, 1994, J BIOL CHEM, V269, P7645